Furthermore, the use of kinase inhibitors of EGFR [61], ALK [62], and RET [63], has been beneficial in about 10–15%, 5–7%, and 1.9% of NSCLC patients, respectively. The gene discussed is ALK; the disease is non-small cell lung carcinoma.